tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

CLColgate-Palmolive

Consumer staples · Cosmetics · NYSE

Colgate-Palmolive Company (together with its subsidiaries, “we,” “us,” “our,” the “Company” or “Colgate-Palmolive”) is a caring, innovative growth company united behind our purpose to reimagine a healthier future for all people, their pets and our planet. 10-K, Item 1

Employees
33,600
Headquarters
New York, NY
CEO
Noel R. Wallace
Next results
around Jan 29, 2027
Compare with peers → Embed

What CL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Facts only; most of these sales are routine, such as selling shares from vesting stock awards.

Trading plans adopted or ended

InsiderWhatDateSharesRuns toReported in
Jennifer M. Daniels
Chief Legal Officer and Secretary
Adopted 10b5-1 plan May 1, 2025 up to 6,000 Dec 5, 2025 10-Q Aug 1, 2025
The company's description
On May 1, 2025, Jennifer M. Daniels, the Company’s Chief Legal Officer and Secretary, entered into a pre-arranged trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the “10b5-1 Plan”) as part of her long-term asset diversification, tax and financial planning strategy. The 10b5-1 Plan provides for the sale, subject to certain price limits, of up to 6,000 shares of the Company’s common stock in the aggregate and terminates on December 5, 2025, unless terminated sooner in accordance with its terms. The 10b5-1 Plan was entered into during an open insider trading window and no sales will commence under the plan until completion of the required cooling off period under Rule 10b5-1.
Noel R. Wallace
Chairman, President and Chief Executive
Adopted 10b5-1 plan Aug 21, 2024 up to 100,000 May 23, 2025 10-Q Oct 25, 2024
The company's description
On August 21, 2024, Noel R. Wallace, the Company’s Chairman, President and Chief Executive Officer, entered into a pre-arranged trading plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the “10b5-1 Plan”). The 10b5-1 Plan provides for the sale, subject to certain price limits, of up to 100,000 shares of the Company’s common stock in the aggregate and terminates on May 23, 2025, unless terminated sooner in accordance with its terms. The 10b5-1 Plan was entered into during an open insider trading window and no sales will commence under the plan until completion of the required cooling off period under Rule 10b5-1. Mr. Wallace entered into the 10b5-1 Plan as part of his long-term asset diversification, tax and financial planning strategy. Assuming all shares subject to the 10b5-1 Plan are sold, Mr. Wallace will continue to be meaningfully invested in the Company’s stock and will continue to significantly exceed the Company’s rigorous stock ownership guidelines, which require Mr. Wallace to maintain stock ownership of at least eight times his annual base salary.

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 28, 2023.

Form 144 notices of planned sales

FiledSellerSharesValueShares came from10b5-1 planForm 4 sales after
Nov 5, 2026 NORRINGTON LORRIE M
Officer
4,170 $414,123 Exercise of employee stock options none given 4,170 shares from Nov 5, 2026
Nov 5, 2026 Wallace Noel R.
Officer
20,000 $2,005,163 Vesting of restricted stock unit awards none given 20,000 shares from Nov 5, 2026
Nov 4, 2026 Tsourapas Panagiotis
Officer
19,938 $1,968,710 Exercise of employee stock options none given 19,938 shares from Nov 4, 2026
Nov 4, 2026 Hazlin John
Officer
23,376 $2,317,683 Exercise of employee stock options none given 23,376 shares from Nov 4, 2026
Aug 24, 2026 Tsourapas Panagiotis
Officer
10,000 $920,477 Vesting of performance share unit awards; Vesting of restricted stock unit awards none given 10,000 shares from Aug 24, 2026
Aug 6, 2026 CAHILL JOHN T
Director
4,170 $389,358 Exercise of employee stock options none given 4,170 shares from Aug 6, 2026
Aug 5, 2026 Wallace Noel R.
Officer
161,021 $14,897,912 Exercise of employee stock options none given 161,021 shares from Aug 5, 2026
Aug 4, 2026 Wallace Noel R.
Officer
161,021 $14,800,720 Exercise of employee stock options none given 322,042 shares from Aug 4, 2026
Aug 4, 2026 CAHILLANE STEVEN A
Officer
1,762 $159,584 Exercise of employee stock options none given none found
Feb 12, 2026 Tsourapas Panagiotis
Officer
15,000 $1,467,111 Exercise of employee stock options none given none found
Feb 11, 2026 Tsourapas Panagiotis
Officer
35,000 $3,311,325 Exercise of employee stock options none given none found
Feb 10, 2026 Hazlin John
Officer
20,989 $1,978,211 Exercise of employee stock options none given none found
Feb 4, 2026 Daniels Jennifer
Officer
22,000 $2,075,398 Exercise of employee stock options none given none found
Feb 4, 2026 Wallace Noel R.
Officer, Director
45,568 $4,279,497 Vesting of performance share unit award none given none found
Feb 4, 2026 SUTULA STANLEY J III
Officer
97,843 $9,223,284 Exercise of employee stock options none given none found

From the Form 144 XML filed with the SEC, since Feb 4, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Work on CL in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/CL/export.csv") into a cell.